Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Epcoritamab with Lenalidomide and Tafasitamab for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, The ECLAT Trial

Trial Status: active

This phase II trial studies how well epcoritamab with lenalidomide and tafasitamab work in treating patients with diffuse large B-cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab is a bispecific antibody. Antibodies are proteins made by the immune system to fight infections and other possible harms to the body. A bispecific antibody is developed in the laboratory to bind to two different proteins. Epcoritamab can bind to specific proteins on two different types of white blood cells called B and T cells. These cells help the body fight cancers and infections. One side of epcoritamab attaches to a protein called CD3 on T cells. The other side of epcoritamab attaches to a protein called CD20 on normal healthy and cancerous B cells. By connecting at the same time to CD3 and CD20, epcoritamab brings T cells and B cells close together and directs the T cells to kill the B cells, including the cancerous B cells. This helps kill cancer cells. Lenalidomide is a drug that works against cancer cells by helping to change or control the functioning of the immune system. Tafasitamab is a monoclonal antibody that blocks a protein in the body that can cause tumors to grow. Monoclonal antibodies target and destroy only certain cells in the body. This selective targeting may help protect healthy cells from damage. It targets the CD19 antigen which are expressed on the surface of B-cells, which then signals the immune system’s natural killer cells to destroy those B-cells, which helps the body’s immune system target the cancer cells and destroy them. Giving the combination of epcoritamab with lenalidomide and tafasitamab may be an effective treatment for patients with relapsed/refractory diffuse large B-cell lymphoma.